Global Colorectal Cancer Market

Colorectal Cancer Comprehensive Study by Type (Lymphoma, Carcinoids, Turcot Syndrome, Adenocarcinoma, Juvenile Polyposis Coli, Peutz-Jeghers Syndrome (PJS), Familial Colorectal Cancer (FCC), Gastrointestinal Stromal Tumors (GIST), Others), Application (Hospitals and Clicnics, Macroscopy, Microscopy, Immunochemistry, Staging, Tumor Budding, Others), Drug Class (Chemotherapy, Immunotherapy) Players and Region - Global Market Outlook to 2030

Colorectal Cancer Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Colorectal Cancer
Colorectal cancer market is growing owing to increasing instances globally, research and development and adoption of Anti-PD1 drugs such as Opdivo and Keytruda owing to their target oriented mechanism. In addition, recently increasing application of advanced drugs and therapies such as Avastin reducing the death ratio from colorectal cancer potentially growing the market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Colorectal Cancer is a fragmented market due to the presence of less players. The players are focusing on strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Colorectal Cancer market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Bayer HealthCare Pharmaceuticals (Germany), Boehringer Ingelheim (Germany), Taiho Pharmaceutical (Japan), Eli Lilly and Company (United States), Pfizer, Inc. (United States), Debiopharm (Switzerland), Vaccinogen (United States), Aeterna Zentaris (United States), Keryx (United States) and Spectrum Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Taiho Pharmaceutical (Japan), Mologen (Germany) and Amgen (United States).

Segmentation Overview
AMA Research has segmented the market of Global Colorectal Cancer market by Type (Lymphoma, Carcinoids, Turcot Syndrome, Adenocarcinoma, Juvenile Polyposis Coli, Peutz-Jeghers Syndrome (PJS), Familial Colorectal Cancer (FCC), Gastrointestinal Stromal Tumors (GIST) and Others), Application (Hospitals and Clicnics, Macroscopy, Microscopy, Immunochemistry, Staging, Tumor Budding and Others) and Region.



On the basis of geography, the market of Colorectal Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Class, the sub-segment i.e. Chemotherapy will boost the Colorectal Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing chemotherapeutic regimens and generics treatments.

Market Growth Drivers:
Increasing Prevalence across Economies, Increasing Adoption of anti-PD1 drugs and Growing Efficiency Avastin Therapy

Challenges:
lack of Advanced Healthcare Infrastructure in the Emerging Economies

Restraints:
Stringent Government Regulations and Lack of Skilled Professional for Treatment

Opportunities:
Rising Awareness about Early Screening and Diagnosis and Improving Healthcare Services

Market Leaders and their expansionary development strategies
In January 2023, Takeda announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau.
In February 2023, Cancer surgery experts launched a network of hospitals across India to support a country-wide clinical trial exploring how giving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back.


Key Target Audience
Healthcare Institutes, Industry Association, Downstream Vendors, Government Bodies, Business Research and consulting Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Lymphoma
  • Carcinoids
  • Turcot Syndrome
  • Adenocarcinoma
  • Juvenile Polyposis Coli
  • Peutz-Jeghers Syndrome (PJS)
  • Familial Colorectal Cancer (FCC)
  • Gastrointestinal Stromal Tumors (GIST)
  • Others
By Application
  • Hospitals and Clicnics
  • Macroscopy
  • Microscopy
  • Immunochemistry
  • Staging
  • Tumor Budding
  • Others
By Drug Class
  • Chemotherapy
  • Immunotherapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence across Economies
      • 3.2.2. Increasing Adoption of anti-PD1 drugs
      • 3.2.3. Growing Efficiency Avastin Therapy
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advanced Healthcare Infrastructure in the Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Growing chemotherapeutic regimens and generics treatments.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Colorectal Cancer, by Type, Application, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Colorectal Cancer (Value)
      • 5.2.1. Global Colorectal Cancer by: Type (Value)
        • 5.2.1.1. Lymphoma
        • 5.2.1.2. Carcinoids
        • 5.2.1.3. Turcot Syndrome
        • 5.2.1.4. Adenocarcinoma
        • 5.2.1.5. Juvenile Polyposis Coli
        • 5.2.1.6. Peutz-Jeghers Syndrome (PJS)
        • 5.2.1.7. Familial Colorectal Cancer (FCC)
        • 5.2.1.8. Gastrointestinal Stromal Tumors (GIST)
        • 5.2.1.9. Others
      • 5.2.2. Global Colorectal Cancer by: Application (Value)
        • 5.2.2.1. Hospitals and Clicnics
        • 5.2.2.2. Macroscopy
        • 5.2.2.3. Microscopy
        • 5.2.2.4. Immunochemistry
        • 5.2.2.5. Staging
        • 5.2.2.6. Tumor Budding
        • 5.2.2.7. Others
      • 5.2.3. Global Colorectal Cancer by: Drug Class (Value)
        • 5.2.3.1. Chemotherapy
        • 5.2.3.2. Immunotherapy
      • 5.2.4. Global Colorectal Cancer Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Colorectal Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer HealthCare Pharmaceuticals (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taiho Pharmaceutical (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Debiopharm (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vaccinogen (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aeterna Zentaris (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Keryx (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Spectrum Pharmaceuticals (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Colorectal Cancer Sale, by Type, Application, Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Colorectal Cancer (Value)
      • 7.2.1. Global Colorectal Cancer by: Type (Value)
        • 7.2.1.1. Lymphoma
        • 7.2.1.2. Carcinoids
        • 7.2.1.3. Turcot Syndrome
        • 7.2.1.4. Adenocarcinoma
        • 7.2.1.5. Juvenile Polyposis Coli
        • 7.2.1.6. Peutz-Jeghers Syndrome (PJS)
        • 7.2.1.7. Familial Colorectal Cancer (FCC)
        • 7.2.1.8. Gastrointestinal Stromal Tumors (GIST)
        • 7.2.1.9. Others
      • 7.2.2. Global Colorectal Cancer by: Application (Value)
        • 7.2.2.1. Hospitals and Clicnics
        • 7.2.2.2. Macroscopy
        • 7.2.2.3. Microscopy
        • 7.2.2.4. Immunochemistry
        • 7.2.2.5. Staging
        • 7.2.2.6. Tumor Budding
        • 7.2.2.7. Others
      • 7.2.3. Global Colorectal Cancer by: Drug Class (Value)
        • 7.2.3.1. Chemotherapy
        • 7.2.3.2. Immunotherapy
      • 7.2.4. Global Colorectal Cancer Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Colorectal Cancer: by Type(USD Million)
  • Table 2. Colorectal Cancer Lymphoma , by Region USD Million (2018-2023)
  • Table 3. Colorectal Cancer Carcinoids , by Region USD Million (2018-2023)
  • Table 4. Colorectal Cancer Turcot Syndrome , by Region USD Million (2018-2023)
  • Table 5. Colorectal Cancer Adenocarcinoma , by Region USD Million (2018-2023)
  • Table 6. Colorectal Cancer Juvenile Polyposis Coli , by Region USD Million (2018-2023)
  • Table 7. Colorectal Cancer Peutz-Jeghers Syndrome (PJS) , by Region USD Million (2018-2023)
  • Table 8. Colorectal Cancer Familial Colorectal Cancer (FCC) , by Region USD Million (2018-2023)
  • Table 9. Colorectal Cancer Gastrointestinal Stromal Tumors (GIST) , by Region USD Million (2018-2023)
  • Table 10. Colorectal Cancer Others , by Region USD Million (2018-2023)
  • Table 11. Colorectal Cancer: by Application(USD Million)
  • Table 12. Colorectal Cancer Hospitals and Clicnics , by Region USD Million (2018-2023)
  • Table 13. Colorectal Cancer Macroscopy , by Region USD Million (2018-2023)
  • Table 14. Colorectal Cancer Microscopy , by Region USD Million (2018-2023)
  • Table 15. Colorectal Cancer Immunochemistry , by Region USD Million (2018-2023)
  • Table 16. Colorectal Cancer Staging , by Region USD Million (2018-2023)
  • Table 17. Colorectal Cancer Tumor Budding , by Region USD Million (2018-2023)
  • Table 18. Colorectal Cancer Others , by Region USD Million (2018-2023)
  • Table 19. Colorectal Cancer: by Drug Class(USD Million)
  • Table 20. Colorectal Cancer Chemotherapy , by Region USD Million (2018-2023)
  • Table 21. Colorectal Cancer Immunotherapy , by Region USD Million (2018-2023)
  • Table 22. South America Colorectal Cancer, by Country USD Million (2018-2023)
  • Table 23. South America Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 24. South America Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 25. South America Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 26. Brazil Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 27. Brazil Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 28. Brazil Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 29. Argentina Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 30. Argentina Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 31. Argentina Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 32. Rest of South America Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 35. Asia Pacific Colorectal Cancer, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 39. China Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 40. China Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 41. China Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 42. Japan Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 43. Japan Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 44. Japan Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 45. India Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 46. India Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 47. India Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 48. South Korea Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 49. South Korea Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 50. South Korea Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 51. Taiwan Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 52. Taiwan Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 53. Taiwan Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 54. Australia Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 55. Australia Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 56. Australia Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 60. Europe Colorectal Cancer, by Country USD Million (2018-2023)
  • Table 61. Europe Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 62. Europe Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 63. Europe Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 64. Germany Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 65. Germany Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 66. Germany Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 67. France Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 68. France Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 69. France Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 70. Italy Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 71. Italy Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 72. Italy Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 73. United Kingdom Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 74. United Kingdom Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 75. United Kingdom Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 76. Netherlands Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 77. Netherlands Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 78. Netherlands Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 79. Rest of Europe Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 80. Rest of Europe Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 81. Rest of Europe Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 82. MEA Colorectal Cancer, by Country USD Million (2018-2023)
  • Table 83. MEA Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 84. MEA Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 85. MEA Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 86. Middle East Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 87. Middle East Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 88. Middle East Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 89. Africa Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 90. Africa Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 91. Africa Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 92. North America Colorectal Cancer, by Country USD Million (2018-2023)
  • Table 93. North America Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 94. North America Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 95. North America Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 96. United States Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 97. United States Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 98. United States Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 99. Canada Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 100. Canada Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 101. Canada Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 102. Mexico Colorectal Cancer, by Type USD Million (2018-2023)
  • Table 103. Mexico Colorectal Cancer, by Application USD Million (2018-2023)
  • Table 104. Mexico Colorectal Cancer, by Drug Class USD Million (2018-2023)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Colorectal Cancer: by Type(USD Million)
  • Table 118. Colorectal Cancer Lymphoma , by Region USD Million (2025-2030)
  • Table 119. Colorectal Cancer Carcinoids , by Region USD Million (2025-2030)
  • Table 120. Colorectal Cancer Turcot Syndrome , by Region USD Million (2025-2030)
  • Table 121. Colorectal Cancer Adenocarcinoma , by Region USD Million (2025-2030)
  • Table 122. Colorectal Cancer Juvenile Polyposis Coli , by Region USD Million (2025-2030)
  • Table 123. Colorectal Cancer Peutz-Jeghers Syndrome (PJS) , by Region USD Million (2025-2030)
  • Table 124. Colorectal Cancer Familial Colorectal Cancer (FCC) , by Region USD Million (2025-2030)
  • Table 125. Colorectal Cancer Gastrointestinal Stromal Tumors (GIST) , by Region USD Million (2025-2030)
  • Table 126. Colorectal Cancer Others , by Region USD Million (2025-2030)
  • Table 127. Colorectal Cancer: by Application(USD Million)
  • Table 128. Colorectal Cancer Hospitals and Clicnics , by Region USD Million (2025-2030)
  • Table 129. Colorectal Cancer Macroscopy , by Region USD Million (2025-2030)
  • Table 130. Colorectal Cancer Microscopy , by Region USD Million (2025-2030)
  • Table 131. Colorectal Cancer Immunochemistry , by Region USD Million (2025-2030)
  • Table 132. Colorectal Cancer Staging , by Region USD Million (2025-2030)
  • Table 133. Colorectal Cancer Tumor Budding , by Region USD Million (2025-2030)
  • Table 134. Colorectal Cancer Others , by Region USD Million (2025-2030)
  • Table 135. Colorectal Cancer: by Drug Class(USD Million)
  • Table 136. Colorectal Cancer Chemotherapy , by Region USD Million (2025-2030)
  • Table 137. Colorectal Cancer Immunotherapy , by Region USD Million (2025-2030)
  • Table 138. South America Colorectal Cancer, by Country USD Million (2025-2030)
  • Table 139. South America Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 140. South America Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 141. South America Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 142. Brazil Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 143. Brazil Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 144. Brazil Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 145. Argentina Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 146. Argentina Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 147. Argentina Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 148. Rest of South America Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 149. Rest of South America Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 150. Rest of South America Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 151. Asia Pacific Colorectal Cancer, by Country USD Million (2025-2030)
  • Table 152. Asia Pacific Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 153. Asia Pacific Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 154. Asia Pacific Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 155. China Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 156. China Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 157. China Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 158. Japan Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 159. Japan Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 160. Japan Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 161. India Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 162. India Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 163. India Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 164. South Korea Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 165. South Korea Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 166. South Korea Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 167. Taiwan Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 168. Taiwan Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 169. Taiwan Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 170. Australia Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 171. Australia Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 172. Australia Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 173. Rest of Asia-Pacific Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 174. Rest of Asia-Pacific Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 175. Rest of Asia-Pacific Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 176. Europe Colorectal Cancer, by Country USD Million (2025-2030)
  • Table 177. Europe Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 178. Europe Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 179. Europe Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 180. Germany Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 181. Germany Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 182. Germany Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 183. France Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 184. France Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 185. France Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 186. Italy Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 187. Italy Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 188. Italy Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 189. United Kingdom Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 190. United Kingdom Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 191. United Kingdom Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 192. Netherlands Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 193. Netherlands Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 194. Netherlands Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 195. Rest of Europe Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 196. Rest of Europe Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 197. Rest of Europe Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 198. MEA Colorectal Cancer, by Country USD Million (2025-2030)
  • Table 199. MEA Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 200. MEA Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 201. MEA Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 202. Middle East Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 203. Middle East Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 204. Middle East Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 205. Africa Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 206. Africa Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 207. Africa Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 208. North America Colorectal Cancer, by Country USD Million (2025-2030)
  • Table 209. North America Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 210. North America Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 211. North America Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 212. United States Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 213. United States Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 214. United States Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 215. Canada Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 216. Canada Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 217. Canada Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 218. Mexico Colorectal Cancer, by Type USD Million (2025-2030)
  • Table 219. Mexico Colorectal Cancer, by Application USD Million (2025-2030)
  • Table 220. Mexico Colorectal Cancer, by Drug Class USD Million (2025-2030)
  • Table 221. Research Programs/Design for This Report
  • Table 222. Key Data Information from Secondary Sources
  • Table 223. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Colorectal Cancer: by Type USD Million (2018-2023)
  • Figure 5. Global Colorectal Cancer: by Application USD Million (2018-2023)
  • Figure 6. Global Colorectal Cancer: by Drug Class USD Million (2018-2023)
  • Figure 7. South America Colorectal Cancer Share (%), by Country
  • Figure 8. Asia Pacific Colorectal Cancer Share (%), by Country
  • Figure 9. Europe Colorectal Cancer Share (%), by Country
  • Figure 10. MEA Colorectal Cancer Share (%), by Country
  • Figure 11. North America Colorectal Cancer Share (%), by Country
  • Figure 12. Global Colorectal Cancer share by Players 2023 (%)
  • Figure 13. Global Colorectal Cancer share by Players (Top 3) 2023(%)
  • Figure 14. Global Colorectal Cancer share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 18. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 20. Bayer HealthCare Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Bayer HealthCare Pharmaceuticals (Germany) Revenue: by Geography 2023
  • Figure 22. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 24. Taiho Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Taiho Pharmaceutical (Japan) Revenue: by Geography 2023
  • Figure 26. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 28. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Debiopharm (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Debiopharm (Switzerland) Revenue: by Geography 2023
  • Figure 32. Vaccinogen (United States) Revenue, Net Income and Gross profit
  • Figure 33. Vaccinogen (United States) Revenue: by Geography 2023
  • Figure 34. Aeterna Zentaris (United States) Revenue, Net Income and Gross profit
  • Figure 35. Aeterna Zentaris (United States) Revenue: by Geography 2023
  • Figure 36. Keryx (United States) Revenue, Net Income and Gross profit
  • Figure 37. Keryx (United States) Revenue: by Geography 2023
  • Figure 38. Spectrum Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 39. Spectrum Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 40. Global Colorectal Cancer: by Type USD Million (2025-2030)
  • Figure 41. Global Colorectal Cancer: by Application USD Million (2025-2030)
  • Figure 42. Global Colorectal Cancer: by Drug Class USD Million (2025-2030)
  • Figure 43. South America Colorectal Cancer Share (%), by Country
  • Figure 44. Asia Pacific Colorectal Cancer Share (%), by Country
  • Figure 45. Europe Colorectal Cancer Share (%), by Country
  • Figure 46. MEA Colorectal Cancer Share (%), by Country
  • Figure 47. North America Colorectal Cancer Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Merck KGaA (Germany)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Boehringer Ingelheim (Germany)
  • Taiho Pharmaceutical (Japan)
  • Eli Lilly and Company (United States)
  • Pfizer, Inc. (United States)
  • Debiopharm (Switzerland)
  • Vaccinogen (United States)
  • Aeterna Zentaris (United States)
  • Keryx (United States)
  • Spectrum Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Taiho Pharmaceutical (Japan) , Mologen (Germany) , Amgen (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 245 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Colorectal Cancer Market Quantitative research analysis
Global Colorectal Cancer Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Bayer HealthCare Pharmaceuticals (Germany), Boehringer Ingelheim (Germany), Taiho Pharmaceutical (Japan), Eli Lilly and Company (United States), Pfizer, Inc. (United States), Debiopharm (Switzerland), Vaccinogen (United States), Aeterna Zentaris (United States), Keryx (United States) and Spectrum Pharmaceuticals (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing chemotherapeutic regimens and generics treatments." is seen as one of major influencing trends for Colorectal Cancer Market during projected period 2023-2030.
The Colorectal Cancer market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Colorectal Cancer Market Report?

Have a Query? Click Here

Other Related Reports

Extremity Reconstruction Comprehensive Study by Type (Upper Extremity (Shoulder Reconstruction(Partial Shoulder Replacement, Total Standard Replacement, Stemless Total Shoulder Replacement, Total Rev...
$ 3750
Pediatric Brain Tumor Comprehensive Study by Type (Gliomas, Mixed neuronal-glial tumors, Embryonal tumors, Choroid plexus papilloma/carcinoma, Non-neuroepithelial tissue tumors, Meningeal Tumors, Oth...
$ 3500
Head and Neck Cancer Diagnostics Comprehensive Study by Type (Diagnostic imaging equipment, Endoscopy screening equipment, Bioscopy screening tests, Blood tests, Dental diagnostic), Application (Hosp...
$ 3750
Implantable Heart Pacemaker Comprehensive Study by Type (Single Chamber, Dual-Chamber, Biventricular Pacemaking), Application (Heart Block, Sick Sinus Syndrome, Diagnosing Heart Diseases, Others), Pa...
$ 3650
Orthopaedics Comprehensive Study by Application (Fracture Management, Joint Replacement, Orthopedic Surgery, Pediatric Assessment, Pediatric Assessment), Area of Treatment (Trauma, Spine, Knee, Hip),...
$ 3350
Type 1 Diabetes Comprehensive Study by Application (Hospitals, Diagnostic clinics), End Users (Adults, Hospitals and Clinics, Homecare Providers), Product (Insulin, Blood Glucose Monitoring Devices, ...
$ 3500